Safety of varenicline in patients with mental illness

Primary Psychiatry

Volumn 17, Issue 9, 2010, Pages 60-66

  Lorenz, Raymond A ^a,b   Whitley, Heather P ^a,c   McCoy, Emily K ^a  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PLACEBO; VARENICLINE;

AGGRESSION; BLOOD PRESSURE; CLINICAL TRIAL; CONVULSION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HOSTILITY; HUMAN; INSOMNIA; LOW DRUG DOSE; MENTAL DISEASE; NAUSEA; NICOTINE REPLACEMENT THERAPY; PSYCHOSIS; REVIEW; SEIZURE; SIDE EFFECT; SMOKING CESSATION; SUICIDAL IDEATION; THORAX PAIN; TOBACCO DEPENDENCE; UNPLEASANT DREAM; VERTIGO; WEIGHT GAIN;

EID: 78649658079     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Hays JT, Ebbert JO, Sood AS. Efficacy and safety of varenicline for smoking cessation. Am J Med. 2008;121(4 suppl 1):S32-S42.
2. Centers for Disease Control and Prevention. Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses-United States, 1997-2001. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm5425a1.htm. Accessed July 27, 2010.
3. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population based prevalence study. JAMA. 2000;284(20):2606-2610.
4. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.
5. Erratum in: JAMA. 2006;296(11):1355.
6. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
7. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561-1568.
8. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166(15):1571-1577.
9. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release buproprion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
10. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
11. Whitley HP, Moorman KL. Varenicline: a review of the literature and place in therapy. Pharmacy Practice. 2007;5(2):51-58.
12. Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497-511.
13. Knight C, Howard P, Baker CL, Marton JP. The cost effectiveness of an extended course (12 +12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. 2010;13(2):209-214.
14. Chantix [package insert]. New York, NY: Pfizer Labs; 2009.
15. Keating GM, Siddiqui MA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs. 2006;20(11):945-960.
16. ISMP. Strong safety signals seen for new varenicline risks. Available at: www.ismp.org/docs/vareniclinestudy.asp. Accessed July 27, 2010.
17. Saul S. F.A.A. bans antismoking drug, citing side effects. New York Times. May 22, 2008. Available at: www.nytimes.com/2008/05/22/business/22drug.html. Accessed August 4, 2010.
18. U.S. Food and Drug Administration. Information for healthcare professionals: varenicline (marketed as chantix) and bupropion (marketed as zyban, wellbutrin, and generics). Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm. Accessed July 28, 2010.
19. U.S. Food and Drug Administration. Early communication about an ongoing safety review: varenicline (marketed as chantix). Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070765.htm. Accessed July 28, 2010.
20. U.S. Food and Drug Administration. Public health advisory: important information on chantix (varenicline). Available at: www.fda.gov/cder/drug/advisory/varenicline.htm. Accessed July 28, 2010.
21. Kutscher EC, Stanley M, Oehlke K. Chantix-induced mental status changes in a young healthy female. S D Med. 2009;62(5):193,195.
22. Laine P, Marttlia J, Lindeman S. Hallucinations in the context of varenicline withdrawal. Am J Psychiatry. 2009;166(5):619-620.
23. Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf. 2009;32(6):499-507.
24. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behavior: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
25. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr. 2008;13(6):511-514.
26. Pirmoradi P, Roshan S, Nadeem SS. Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. Am J Health Syst Pharm. 2008;65(17):1624-1626.
27. Lyon GJ. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission. J Clin Psychopharmacol. 2008;28(6):720-721.
28. Raidoo BM and Kutscher EC. Visual hallucinations associated with varenicline: a case report. J Med Case Reports. 2009;3:7560.
29. Morstad AE, Kutscher EC, Kennedy WK, Carnahan RM. Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother. 2008;42(2):288-289.
30. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164(8):1269-1270.
31. DiPaula BA, Thomas MD. Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy. 2009;29(7):852-857.
32. Alhatem F, Black JE. Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol. 2009;32(2):117-118.
33. Liu ME, Tsai SJ, Yang ST. Varenicline-induced mixed mood and psychotic episode in a patient with schizoaffective disorder. CNS Spectr. 2009;14(7):346.
34. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164(8):1269.
35. Purvis TL, Mambourg SE, Balvanz TM, Magallon HE, Pham RH. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother. 2009;43(5):862-867.
36. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103(1):146-154.
37. Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry. 2008;69(6):1016.
38. Fatemi SH. Varenicline efficacy and safety in a subject with schizophrenia. Schizophrenia Res. 2008;103(1-3):328-329.
39. Ochoa EL. Varenicline reduced smoking behavior in a mentally ill person. J Psychopharmacol. 2009;23(3):340-341.
40. McClure JB, Swan GE, Jack L, et al. Mood, side effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med. 2009;24(5):563-569.
41. Phillip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: an 8 week, open label study. J Clin Psychiatry. 2009;70(7):1026-1031.
42. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009;65(2):144-149.
43. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol. 2006;70(3):801-805.
44. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635-645.
45. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord. 2009;11(8):787-806.
46. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180(3):305-313.
47. Rollema H, Guanowsky V, Mineur YS, et al. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol. 2009;605(1-3):114-116.
48. Tsoh JY, Humfleet GL, Munoz RF, Reus VI, Hartz DT, Hall SM. Development of major depression after treatment for smoking cessation. Am J Psychiatry. 2000;157(3):368-374.
49. Whitley HP, Moorman KL. Interference with smoking cessation effects of varenicline after administration of immediate release amphetamine-dextroamphetamine. Pharmacotherapy. 2007;27(10):1440-1445.
50. Heron MP, Hoyert DL, Xu JQ, Scott C, Tejada-Vera B. Deaths: preliminary data for 2006. Natl Vital Stat Rep. 2008;56(16). Available at: www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_16.pdf. Accessed July 28, 2010.
51. Centers for Disease Control and Prevention. Suicide. Facts at a Glance. Summer 2009. Available at: www.cdc.gov/violenceprevention/pdf/Suicide-DataSheet-a.pdf. Accessed August 4, 2010.
52. U.S. Food and Drug Administration. Information for healthcare professionals: varenicline (marketed as chantix). Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124818.htm. Accessed July 28, 2010.